Advanced Particulate Analysis and DNA Detection Services for Biologics
At Vista Biologicals, Particulate Analysis is a critical component of our quality and safety testing framework for biologics and biopharmaceutical products. Our analytical team employs advanced detection technologies to identify and quantify microscopic particulates, ensuring that every batch meets the highest purity and compliance standards.
As part of our specialized pharmaceutical testing services, particulate analysis is complemented by nucleic acid testing, including mycoplasma DNA detection and MMV DNA detection (Minute Virus of Mice). These assays help confirm product integrity and eliminate contamination risks across all stages of biologics development and manufacturing.
Our methods align with current regulatory guidelines and are designed to deliver rapid, reliable results that support GMP-compliant release, comparability studies, and ongoing stability monitoring.
Key Capabilities
- Comprehensive Particulate Profiling
High-resolution particle identification and enumeration for biologics, vaccines, and injectable formulations. - Mycoplasma DNA Detection
Sensitive molecular assays for early identification of mycoplasma contamination, ensuring product purity and cell-culture integrity. - MMV DNA Detection
Precise testing for viral DNA contamination to safeguard biologics manufactured in mammalian systems. - Regulatory-Ready Documentation
Full data reporting and traceability in accordance with ICH, USP, and FDA quality standards.
Our particulate analysis and DNA detection services form a vital part of Vista Biologicals’ integrated analytical and pharmaceutical support. This page will soon be updated with more detailed information about our methodologies, equipment, and validation processes. For now, clients can reach out to our analytical team for guidance on implementing mycoplasma DNA detection, MMV DNA detection, or combined particulate-testing protocols in their biologics programs.
